1h Free Analyst Time
The proteasome inhibitors market is forecasted to grow by USD 4.41 billion during 2024-2029, accelerating at a CAGR of 8.4% during the forecast period. The report on the proteasome inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of hematologic cancers, growing prevalence of multiple myeloma, and expanded application of proteasome inhibitors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The proteasome inhibitors market is segmented as below:
By Product
- VELCADE
- KYPROLIS
- NINLARO
- Others
By Route Of Administration
- Oral
- Intravenous
By End-user
- Hospitals
- Cancer treatment centers
- Specialty clinics
- Research institutes
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the proteasome inhibitors market covers the following areas:
- Proteasome Inhibitors Market sizing
- Proteasome Inhibitors Market forecast
- Proteasome Inhibitors Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by Route of Administration
10 Market Segmentation by End-user
11 Market Segmentation by Distribution Channel
12 Customer Landscape
13 Geographic Landscape
14 Drivers, Challenges, and Opportunity/Restraints
15 Competitive Landscape
16 Competitive Analysis
17 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global proteasome inhibitors market: Amgen Inc., Baxter International Inc., Bristol Myers Squibb Co., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Kezar Life Sciences Inc., LifeSensors Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., QLi5 Therapeutics, Takeda Pharmaceutical Co. Ltd., TG Therapeutics Inc., Thermo Fisher Scientific Inc., and Tocris Bioscience.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advancements in drug development."
According to the report, one of the major drivers for this market is the rising incidence of hematologic cancers.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Baxter International Inc.
- Bristol Myers Squibb Co.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- Johnson and Johnson
- Kezar Life Sciences Inc.
- LifeSensors Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- QLi5 Therapeutics
- Takeda Pharmaceutical Co. Ltd.
- TG Therapeutics Inc.
- Thermo Fisher Scientific Inc.
- Tocris Bioscience
